Abbonarsi

Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial - 28/11/12

Doi : 10.1016/j.ahj.2012.09.011 
Robert J. Mentz, MD a, j, Matthew J. Chung, MD a, j, Mihai Gheorghiade, MD b, , Peter S. Pang, MD c, Mary J. Kwasny, ScD c, Andrew P. Ambrosy, MD d, Muthiah Vaduganathan, MD, MPH e, Christopher M. O'Connor, MD a, Karl Swedberg, MD, PhD f, Faiez Zannad, MD g, Marvin A. Konstam, MD h, Aldo P. Maggioni, MD i
a Duke University Medical Center, Durham, NC 
b Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL 
c Northwestern University Feinberg School of Medicine, Chicago, IL 
d Stanford University School of Medicine, Stanford, CA 
e Massachusetts General Hospital, Boston, MA 
f Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 
g Nancy University, Nancy, France 
h The Cardiovascular Center, Tufts Medical Center, Boston, MA 
i Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, Italy 

Reprint requests: Mihai Gheorghiade. 645 North Michigan Ave. Chicago, IL 60611.

Riassunto

Background

Heart failure (HF) complicated by atrial fibrillation/flutter (AF/AFL) is associated with worse outcomes. However, the clinical profile and outcomes of patients following hospitalization for HF with AF/AFL on initial electrocardiogram (ECG) has not been well studied.

Methods

EVEREST was a randomized trial of vasopressin-2 receptor blockade, in addition to standard therapy, in 4133 patients hospitalized with HF with ejection fraction ≤40%. A post hoc analysis was performed comparing the clinical characteristics and outcomes [all-cause mortality and cardiovascular mortality/HF hospitalization] of patients with AF/AFL versus sinus rhythm (SR) on baseline ECG, which were centrally analyzed. Times to events were compared using log-rank tests and Cox regression models.

Results

Of the 4133 patients, 1195 (29%) were classified with AF/AFL and 2071(50%) with SR. The remaining patients (21%) were excluded because ECGs were unavailable (n = 106), rhythm was paced (n = 727), or junctional/other supraventricular (n = 34). AF/AFL patients were older, with increased weight, faster heart rate, higher blood urea nitrogen, and natriuretic peptide levels compared to SR patients. Anticoagulation was prescribed in 67% of AF/AFL patients on discharge. AF/AFL patients were less likely to receive β-blockers or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (all P < .05). After risk adjustment, AF/AFL was associated with increased mortality (hazard ratio 1.23; 95% CI, 1.04-1.46) and cardiovascular mortality/HF hospitalization (hazard ratio 1.26; 95% CI, 1.07-1.47).

Conclusion

AF/AFL on initial ECG in patients hospitalized with HF with reduced ejection fraction is associated with lower use of evidence-based therapies and increased mortality and rehospitalization compared to patients in SR.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Hector O. Ventura, MD served as guest editor for this article.


© 2012  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 164 - N° 6

P. 884 - dicembre 2012 Ritorno al numero
Articolo precedente Articolo precedente
  • The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
  • Lars Gullestad, Thor Ueland, John Kjekshus, Ståle H. Nymo, Johannes Hulthe, Pieter Muntendam, John J.V. McMurray, John Wikstrand, Pål Aukrust
| Articolo seguente Articolo seguente
  • Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: A double-blind randomized controlled feasibility study
  • Martin Stout, Garry A. Tew, Helen Doll, Irena Zwierska, Nicola Woodroofe, Kevin S. Channer, John M. Saxton

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.